基本説明
Thoroughly updated and expanded their survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma.
Full Description
In this second edition of their critically acclaimed book, Ronald Bukowski, Robert Motzer, and Robert Figlin have thoroughly updated and expanded their survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. A panel of internationally renowned contributors explores the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. The discussion includes the specific biology of selected target molecules or receptors and the various agents that inhibit these targets, including full chapters devoted to drugs that selectively inhibit receptor tyrosine kinases, such as sunitinib and axitinib.Further attention is paid to leading-edge strategies that target and inhibit tumor associated angiogenesis and block the vascular endothelial growth factor pathway. Comprehensive and authoritative, "Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Second Edition" is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by the pioneers of the field.
Contents
Ch 1. Targeted Therapy for Metastatic Renal Cell Carcinoma Ronald M. Bukowski, Robert A. Figlin, and Robert Motzer Ch 2. Molecular Genetics of Inherited Renal Cell Carcinoma: Identification of Targets in the Hereditary Syndromes W. Marston Linehan, Nadeem Dhanani, Cathy Vocke, and Gennady Bratslavsky Ch 3. Molecular Targets in Renal Tumors: Pathologic Assessment Ming Zhou 4.Cytokines: Therapeutic Results and Molecular Basis of Activity Thomas Hutson and Ernest C. Borden Ch 5. VHL and HIF in Clear Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications William Kaelin and Daniel J. George Ch 6. Vascular Endothelial Growth Factor (VEGF): Biologic Aspects and Clinical Approaches W. Kimryn Rathmell and Brian Rini Ch 7A. VEGF and PDGF Receptors: Biologic Relevance and Clinical Approaches to Inhibition John S. Lam, Robert Figlin, and Arie Belldegrun Ch 7B. Sunitinib and Axitinib in Renal Cell Carcinoma Robert Motzer Ch 7C. Sorafenib in Renal Cell Carcinoma Saby George and Ronald M. Bukowski Ch 7D. Additional Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: Brian Rini Ch 8. Integrin a5ss1 as a Novel Therapeutic Target in Renal Cell Carcinoma Vanitha Ramakrishnan, Vinay Bhaskar, Melvin Fox, Keith Wilson, John Cheville, and Barbara Finck Ch 9A. Carbonic Anydrase IX: Biological and Clinical Approaches Arie Belldegrun, Robert A. Figlin, and Brian Shuch Ch 9B. Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma: Biologic and Clinical Studies Jeannette C. Oosterwijk-Wakka, Otto C. Boerman, Peter F. A. Mulders, and Egbert Oosterwijk Ch 10. Chemokines in Renal Cell Carcinoma : Implications for Tumor Angiogenesis and Metastasis Karen Reckamp, Robert A. Figlin, and Robert M. Strieter Ch 11. PI3K/Akt/mTOR Pathway: A Growth Proliferation Pathway Daniel Cho, James Mier, and Michael B. Atkins Ch 12. EGFR/HER2: Relevance in Renal Cell Carcinoma Eric Jonasch and Cheryl Walker Ch 13. Proteosome - NFkB Signaling Pathway : Relevance in Renal Cell Carcinoma Ram Ganapathi, Susan A.J. Vaziri, and Jorge Garcia Ch 14. The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma Donald P. Bottaro, Benedetta Peruzzi, and Jean-Baptise Lattouf Ch 15. Smac/DIABLO: A Proapoptotic Molecular Target in Renal Cell Carcinoma Yoichi Mizutani, Akihiro Kawauchi, Benjamin Bonavida, and Tsuneharu Mmiki Ch 16. EpH2A: A Novel Target in Renal Cell Carcinoma Mayumi Kawabe, Christopher Herrem, James Finke, and Walter Storkus Ch 17. Restoring Host Immunity: How Coregulatory Molecules are Changing the Approach to Management of Renal Cell Carcinoma Brant A. Inman, Xavier Frigola, Haidong Dong, James C.Yang, and Eugene Kwon Ch 18. The Role of Gangliosides in Renal Cell Carcinoma Phillip Shaheen, Ronald M. Bukowski, and James Finke Ch 19. Tumor Necrosis Factor - Misnomer and Therapeutic Target Marina Parton, Tanya Das, Gaurisankar Sa, James Finke, Tim Eisen, and Charles Tannenbaum Ch 20. Molecularly Targeted Staging Strategies in Renal Cell Carcinoma Mark Nogueira and Hyung Kim 21. Adjuvant therapy for Renal Cell Carcinoma : Targeted Approaches Karin Kader and Christopher Wood
